Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414359 | 1.00 | GRM4 (0.39) | GRM4MAPK14 | |
| Succinimide SCHEMBL27773628 | 0.85 | CRBN (0.33) | GRM4 | |
| SCHEMBL2619233 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL473498 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL30132904 | 0.75 | DYRK1A (0.52) | GRM4 | |
| SCHEMBL11874314 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL352379 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL473390 | 0.75 | GRM4 (0.46) | GRM4MAPK14 | |
| SCHEMBL421235 | 0.75 | DYRK1A (0.52) | GRM4 | |
| SCHEMBL30343654 | 0.72 | RPS6KB1 (0.38) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655637-B | PI3K delta inhibitor and synthetic method and application thereof | 杭州医学院 | 2025-04-11 | — | — | CN | claimed |
| EP-1427743-A4 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES INC (US) | 2007-04-04 | — | — | EP | claimed |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2007-03-15 | — | — | US | claimed |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6962991-B2 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2005-11-08 | — | — | US | claimed |
| US-20040191824-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2004-09-30 | — | — | US | claimed |
| EP-1427743-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | Epoch Biosciences, Inc. (US) | 2004-06-16 | — | — | EP | claimed |
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2003022859-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| US-12522606-B2 | Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy | UNIVERSITY OF WASHINGTON (US) | 2026-01-13 | — | — | US | disclosed |
| CN-116655637-B | PI3K delta inhibitor and synthetic method and application thereof | 杭州医学院 | 2025-04-11 | — | — | CN | disclosed |
| CN-115768764-B | Parallel ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| CN-115768764-A | Fused ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20040191824-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004069838-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| EP-1427743-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | Epoch Biosciences, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003022859-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | GRM4 3095/4885MAPK14 1149/4885 |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | GRM4 86/4885MAPK14 2218/4885 |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | GRM4 3095/4885MAPK14 1149/4885 |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | GRM4 3095/4885MAPK14 1149/4885 |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | PDK2, PDK1, PC | GRM4 1713/4885MAPK14 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.